Nearly 3 years ago, Breakthrough T1D joined forces with Civica Rx, a non-profit pharmaceutical company, to manufacture and distribute low-cost insulins. Starting on January 1, 2026, the first of those insulins, insulin glargine-yfgn (a long-acting insulin interchangeable with Lantus®), will be available for purchase. 5 Pens, No More Than $55 – for anyone While we […] The post Civica long-acting insulin available on January 1, 2026 appeared first on Breakthrough T1D.
